Design and analysis characteristics.

<p>Design and analysis characteristics.</p

The general characteristics of trials.

<p>The general characteristics of trials.</p

Comparison of reporting of essential information in NI trials.

<p>Comparison of reporting of essential information in NI trials.</p

Stratification of the articles according to their journal impact factors.

<p>Stratification of the articles according to their journal impact factors.</p

Flow diagram of trials' selection process.

<p>Flow diagram of trials' selection process.</p

Additional benefit of the new drug mentioned in the publication.

<p><i>Note:</i></p><p>*Percentage is based on 124 trials that mentioned any additional benefit of the new drugs irrespective of whether or not data were shown to support the claim.</p>¶<p>The authors show any analysis or argument of the additional benefit.</p>†<p>Three trials addressed both the safety profile and the method of administration, six trials only addressed the safety profile, and one trial only addressed the method of administration.</p>‡<p>One trial addressed both the method of administration and patient's compliance rate, and four trials addressed only the patient's compliance rate.</p>§<p>Four trials addressed both safety profile and patient's compliance and one trial only addressed the safety profile.</p>¥<p>One trial addressed both better method of administration and cost and one trial only addressed cost.</p

Number and proportion of the three most frequent off-label indications for drugs with at least 5,000 prescriptions (year 2008, multiple counting of off-label indications per prescription).

<p>SABA: Short-acting beta-2-agonist, CGA: Cromoglicic acid, LABA: Long-acting beta-2-agonist, ICS: Inhaled corticosteroid, SAMA: Short-acting muscarinic antagonist, B2A: Beta-2-agonist, nec: not elsewhere classified.</p><p>*Exclusive missing indications.</p><p>Number and proportion of the three most frequent off-label indications for drugs with at least 5,000 prescriptions (year 2008, multiple counting of off-label indications per prescription).</p

Annual period prevalence rates per 10,000 children (≤18 years) between 2004 and 2008.

<p>Annual period prevalence rates per 10,000 children (≤18 years) between 2004 and 2008.</p

Baseline characteristics of statin users and non-statin users.

<p>Baseline characteristics of statin users and non-statin users.</p

Flow chart study population.

<p><u>Legend:</u> CPRD, Clinical Practice Research Datalink; RA, rheumatoid arthritis; DMARD, disease modifying anti-rheumatic drug.</p